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Background: Health technology reassessment (HTR) is “a structured, evidence-based assessment of the clinical, social, ethical, and economic effects of a technology currently used in the healthcare
system, to inform optimal use of that technology in comparison to its alternatives.” The purpose of this study is to describe the key themes in the context of current HTR activities and propose a way
forward for this newly emerging field.
Methods: Data were gathered from a workshop held as part of the 2012 Canadian Agency for Drugs and Technology in Health (CADTH) symposium. The workshop consisted of two panel presentations
followed by discussion; data gathered, including presentations and rich audience discussion transcripts, were analyzed for key themes emerging in the field of HTR using constant comparative analysis.
Results: The language chosen to describe HTR will set the tone for engagement. The identification of champions at multiple levels and political will are essential. Key lessons from international
experience are: disinvestment is difficult, focus on clinical areas not specific technologies, identify clear goals of the HTR agenda. Six key themes were identified to move the HTR agenda forward:
emphasize integration over segregation, focus on development of HTR methods and processes, processes are context-specific but lessons must be shared, build capacity in synergistic interdisciplinary
fields, develop meaningful stakeholder engagement, strengthen postimplementation monitoring and evaluation.
Conclusions: To move this field forward, we must continue to build on international experiences with a focus on developing novel methodological approaches to generating, incorporating, and
implementing evidence into policy and practice.
Keywords: Health technology reassessment, disinvestment, value for money
Technologies, broadly defined as drugs, diagnostic tests, includ-
ing indicators and reagents, devices, equipment and supplies,
medical and surgical procedures, support systems, and organi-
zational and managerial systems used across the spectrum of
health care, are a major source of expenditure within the health-
care system (1). For decades, the healthcare system has focused
on managing the entry of technologies, including the require-
ments for licensure mandated by Health Canada for drugs and
devices. For specific technologies, including new drugs which
must be assessed in Canada by the Common Drug Review, a
demonstration of clinical value and cost-effectiveness is also
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required (2). However, once a technology enters the system,
there is no standardized process for monitoring its use, nor
managing its exit if it is superseded by advances in knowledge
(1;3).
The proposed working definition for health technology
reassessment (HTR) is: “a structured, evidence-based assess-
ment of the clinical, social, ethical, and economic effects of
a technology currently used in the healthcare system, to in-
form optimal use of that technology in comparison to its al-
ternatives.” (4) (Box 1). The language chosen to describe the
assessment of technologies currently in use in the healthcare
system can be influential in setting the tone for engagement.
For example, language such as “disinvestment” and “reinvest-
ment” focus attention on the cost component of technology,
and the potential inference of a foregone conclusion to the
process, rather than the actual goal of HTR; optimizing the
use of technologies in health care and achieving the greatest
clinical benefit with our social dollars. The term HTR is pro-
posed as it is value neutral and does not pre-suppose the out-
come of the process. Although HTR has perhaps traditionally
been thought of as managing the exit of particular technolo-
gies from the system, a complete removal of a technology is
unlikely to be warranted in most circumstances; experience to
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While intimately linked to both health technology assess-
ment (HTA) and disinvestment, HTR is a distinct concept.
While HTA application has been mainly limited to managing the
entrance of “new things” into the healthcare system, HTR is a
process to support on-going evidence informed policy regard-
ing the optimal use of technology throughout the lifecycle of
technology. Technologies undergoing HTR may or may not have
undergone HTA as part of their adoption decision. However, all
technologies selected for HTR are actively being used within
the healthcare system with a requirement to manage their scope
of use. Disinvestment is one potential outcome of HTR; other
outcomes include no change in use, narrowing the scope of use
(including the potential to increase use of a comparator technol-
ogy in place), increasing scope of use and in rare circumstances,
stopping use all together. In the past, HTR has been an implicit
part of HTA as often usage of a competing technology will be
affected by the adoption of a new technology. However, there
is now a desire to see HTR become standard practice with a
goal of optimizing the use of technologies in health care and
achieving the greatest clinical benefit with our social dollars
(1;3;7–9).
A recent systematic review of the literature on HTR identi-
fied eight countries with some evidence of past or current work
related to HTR (10). Many organizations realize the potential
benefits of HTR and are interested in integrating it into their
healthcare system. However, a lack of top-down support, push
back from clinicians, financial and human resource limitations,
and a lack of expertise in health technology reassessment are
inhibiting program development (8;11–14). Several critical fac-
tors for success were also identified, including the importance
of early and ongoing stakeholder engagement, the identification
of champions at multiple levels, embedding HTR into existing
structures if and where appropriate, and developing HTR mod-
els in context that are adaptable (8;12;14;15).
Given the mounting interest in continued assessment be-
yond the adoption decision, the 2012 Canadian Agency for
Drugs and Technology in Health (CADTH) symposium held in
Ottawa, Canada in April 2012 featured a preconference work-
shop entitled Health Technology Reassessment (HTR): Promot-
ing Value and Evidence-Based Practice. The purpose of this
study is to describe the key themes in the context of current HTR
activities and propose a way forward for this newly emerging
field.
METHODS
The workshop was hosted by the Health Technology Assess-
ment Unit at the University Calgary, who are actively engaged
with the provincial Ministry of Health to develop a HTR model
for Alberta, Canada. The workshop was open to all attendees
of the CADTH symposium. Attendees came from a variety of
contexts including representation from provincial, national, and
international HTA agencies, ministries of health, not-for-profit
Table 1. Definitions
Disinvestment: the process of withdrawing (partially or completely) health resources
from those existing healthcare practices, procedures, technologies, and
pharmaceuticals that are deemed to deliver no or low health gain and are thus not
efficient health resource allocations (8).
Health Technology: Any intervention that may be used to promote health, to prevent,
diagnose or treat disease or for rehabilitation or long-term care. This includes the
pharmaceuticals, devices, procedures and organizational systems used in health
care (24).
Health Technology Assessment: a multi-disciplinary field of policy analysis that
examines the medical, economic, social and ethical implications of the incremental
value, diffusion and use of a medical technology in health care (24).
Health Technology Reassessment: a structured, evidence-based assessment of the
clinical, social, ethical and economic effects of a technology currently used in the
healthcare system, to inform optimal use of that technology in comparison to its
alternatives (4).
health agencies, academia, and industry. The workshop began
with a brief presentation to establish a common understanding
of HTR and its development as a field. Two panel presentations
followed. The first panel focused on methodological challenges
and consisted of a health economist, an expert in implementa-
tion science and an international expert in HTR. The second
panel focused on current practices with representation from
three jurisdictions (Alberta, Australia, and United Kingdom)
each at different stages with their HTR programs. During the
panel sessions, each panelist was given 5 minutes to provide an
introduction followed by audience discussion. The workshop
was recorded and transcribed. All data gathered, including pre-
sentations and rich discussion transcripts, were analyzed for key
themes emerging in the field of HTR using constant comparative
analysis.
RESULTS
Themes from International Experiences
The United Kingdom and Australia report the most experi-
ence in HTR. At the national (Medicare) level in Australia,
HTR has been integrated under the responsibility of the De-
partment of Health and Ageing, including the Medical Ser-
vices Advisory Committee (MSAC), which makes recommen-
dations to the Health Minister about what medical services
offer sufficient safety and (cost)effectiveness to warrant pub-
lic subsidy. Since 2009, a Quality Framework for Australia’s
Medicare Benefits Schedule was developed under the auspices
of the MSAC (16). As part of this initiative, the Health Min-
ister commissioned a review of HTA in Australia, with one
outcome being the development of a postmarket surveillance
system that included a parallel approach to HTR. This paral-
lel approach involved a review of individual items (17), which
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Table 2. Summary of Themes
Disinvestment is difficult: Limited success has been achieved internationally.
Focus on clinical areas in addition to specific technologies: changes in utilization of one
technology may impact utilization of a competing technology. Efficiencies in process
may be achieved by reviewing clinical areas as opposed to single technologies.
Clear goals of the HTR agenda are required to prioritize candidate technologies: A
common understanding of the goal supports transparent prioritization of HTR
candidates.
Emphasize integration over segregation: Embed HTR into existing processes.
Focus on development of HTR methods and processes: methodology to measure costs,
benefits, and values is necessary for non-drug technologies
Processes are often context-specific: Learnings from other jurisdictions must be
tempered by local contextual and system realities.
Build capacity in synergistic interdisciplinary fields: Innovative, interdisciplinary teams
of highly skilled people from disciplines such as economics, implementation science,
KT, health services research, policy analysis, change management, evaluation, and
stakeholder engagement are required.
Meaningful stakeholder engagement: An effective strategy should “grab both the
hearts and the minds of stakeholders.” Thoughtful consideration of patient and
public engagement should be undertaken.
Strengthen post-implementation monitoring and evaluation: Post-implementation
monitoring and evaluation must be undertaken with an emphasis on active
monitoring for unintended consequences.
dovetailed with existing HTA processes, as well as a whole-of-
specialty review (17). Both proved to be novel, effective ap-
proaches to engaging clinicians from the beginning of the HTR
process.
For the review of individual items, a proposed scanning
process was adapted to identify appropriate candidates for HTR
(15). Using this process, 156 possible candidates were identi-
fied a nd provided to government for consideration, from which
they identified fifteen for initial rapid review and potential full
HTR (16). Outcomes from review include: an amendment to the
item description such that it better captures the patient group/s
most likely to benefit from any procedure, for example; an in-
crease, decrease or maintenance of the fee; or a complete stop to
public funding of the item. One example of an individual tech-
nology that underwent a complete review was vertebroplasty
for osteoporotic vertebral fractures. The recommendation from
MSAC was that Government stop public funding of this proce-
dure because of a lack of evidence of effectiveness. Some clini-
cians noted their dissent to MSAC’s decision yet concomitantly,
multiple reports from around the world have been developed
supporting MSAC’s position (18).
In ophthalmology, a whole-of-specialty review was con-
ducted. The initial impetus for the review was a government
decision to cut the fee for cataract surgery, which resulted in
dissent from ophthalmologists. The government’s observation
was that advances in cataract surgery technology delivered on
its promise: procedures could be done far more quickly and
safely then when it was first introduced (and priced), so a de-
crease in fee seemed the appropriate market response. The ensu-
ing whole-of-specialty (ophthalmology) review of the Medical
Benefits Schedule was approached collaboratively with oph-
thalmology stakeholders, asking the field what in the schedule
they thought required some modification. Of the sixty-one item
descriptors on the schedule only twenty remained unchanged
through the process. Items were either clarified, modified (e.g.,
refinement of indications and/or eligible patient groups), split,
merged, or entirely removed (17). In all respects, this was con-
sidered a success with good outcomes for all including pa-
tients. The whole-of-specialty approach is now rolling out more
broadly.
In the United Kingdom, the National Health Service (NHS),
through the National Institute for Health and Clinical Excellence
(NICE), has launched a HTR program. NICE has developed two
streams; the “do-not-do” recommendations and the Cochrane
Quality and Productivity Topics. Both are passive HTR activi-
ties resulting in guidance that clinicians may choose to follow.
The “do-not-do” recommendations is a searchable database of
recommendations made since 2007. The recommendations are
identified during the process of guidance development where
NICE’s independent advisory bodies often identify NHS clini-
cal practices that they recommend should be discontinued com-
pletely or should not be used routinely. Each record contains
the “do not do” recommendation and includes additional infor-
mation including the intervention, health topic, the guidance it
comes from (with a link to the relevant paragraph in the guid-
ance), and the other “do not do” recommendations from the
same guidance. Each recommendation also includes the health-
care setting that describes the main clinical environments in
which the intervention or investigation may be initiated.
In addition to the “do-not-do” recommendations, NICE has
also developed the Cochrane Quality and Productivity Topics.
These are based on Cochrane reviews with the goal of helping
the NHS identify practices that could be reduced or stopped
freeing up cash and resources that could reinvested in more
effective practices. NICE’s experience over the past 12 years,
however, is that although reassessment and potential disinvest-
ment has the potential to increase efficiency and quality, actual
cost savings, and therefore the potential for reinvestment has
been less than anticipated. In the year 2011–2012, half of the
efficiency savings came from the freezing of health profession-
als’ salaries, not disinvestment in technologies (19).
An analysis of the shared international experiences resulted
in three common themes emerging:
Disinvestment is difficult. Even in the presence of very strong evidence
that a particular technology is harmful and/or (cost)ineffective,
withdrawing the technology from the healthcare system is dif-
ficult. Players, both within and outside the healthcare system,
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must be prepared for political and professional fall-out. Strong,
unwavering political will is critical.
Focus on clinical areas in addition to specific technologies. It is difficult to tease
out the appropriate scope of use of a particular technology from
the broader pathway of care. Very little done in health care is
done in isolation, but rather procedures and devices are used in
combination with other treatments within a pathway of care. A
change in scope of use of a technology is likely to have ripple ef-
fects, resulting in unintended consequences, such as an increase
in use of an alternative treatment. A clear understanding of the
care pathway within which the technology is embedded, along
with social and ethical implications, is critical. The unintended
consequences may be mitigated by focusing on clinical areas
where multiple comparators can be assessed side-by-side in any
care treatment algorithm. In addition, this approach provides
a natural way for engaging clinicians as one could begin by
approaching a particular department or specialty. Clinical spe-
cialty support of any disinvestment list was described as critical
to moving forward.
Clear goals of the HTR agenda are required to prioritize candidate technologies. If
the focus is actual cost savings, then it is likely that much
could be achieved by focusing on redesigning service delivery
mechanisms, and optimizing the human resources within the
healthcare system. However, if the goal is to optimize the use of
technology, which may include cost-savings, focus must move
to technologies which are misused in the system.
Moving Forward with Health Technology Reassessment: A Call to Action
Analyzing the audience discussion in the context of current
literature and expert presentations, several key themes emerged
to move the field of HTR forward.
Emphasize integration over segregation. Integrating HTR with on-going
work such as the development of clinical practice guidelines
and care pathways, as well as quality improvement initiatives
will likely result in the greatest uptake of HTR. Advocating for
the integration of economic considerations into guideline and
care pathway development will support value for money as one
criterion to inform decisions about what should and should not
be done.
Focus on development of HTR methods and processes. The need for methodol-
ogy to measure costs, benefits, and values is dire. These methods
are particularly necessary for non-drug technologies. Method-
ologies must maximize usefulness for decision makers, and
incorporate outcomes of importance to both clinicians and pa-
tients. In addition, they must represent feasible tools to use
within a policy/decision-making context; they must be relevant,
timely, and interpretable.
Processes are often context-specific. Although there is much to be learned
from processes developed in various jurisdictions, processes
ought to be context-specific. Learnings from other jurisdictions
must be tempered by contextual and system realities, and pro-
cesses are likely to require local adaptation. This might in-
clude retro-fitting new HTR processes to existing policy struc-
tures. Key stakeholders must be engaged in this work. This will
ensure that processes developed are supported by, and meet
the needs of, the system using the outcomes to inform their
decisions.
Build capacity in synergistic interdisciplinary fields. Highly skilled people
are required in a variety of disciplines including: economics,
implementation science, KT, health services research, policy
analysis, change management, evaluation, and stakeholder en-
gagement. It will take innovative teams that are interdisci-
plinary and cross institutional in nature to take on the HTR
challenge.
Meaningful stakeholder engagement. Meaningful stakeholder engage-
ment is crucial. Essential elements to engage stakeholders are:
transparent processes for identifying and prioritizing potential
HTR candidates, involvement throughout the process of evi-
dence generation and review, and authentic meaningful engage-
ment (11;13;14;20). Stakeholders should be defined broadly to
include any group impacted by the resulting decision. As clin-
icians are likely to be an important stakeholder group in any
HTR, an effective strategy should “grab both the hearts and the
minds of clinicians.” Thoughtful consideration of patient and
public engagement should be considered (21).
Strengthen postimplementation monitoring and evaluation. HTR must include a
developed postimplementation monitoring and evaluation pro-
cess with an emphasis on active monitoring for unintended
consequences.
“There are known knowns. These are things we know that
we know. There are known unknowns. That is to say, there are
things that we know we don’t know. But there are also unknown
unknowns. There are things we don’t know we don’t know.
(22)”
Active monitoring for these “unknown unknowns” is crit-
ical to ensure that health outcomes, access, and equity are not
adversely impacted. For example, within a surgical program,
the operation suite will never be un-used. Thus, if one pro-
cedure is stopped, the operational suite time could be filled
with another procedure perhaps equally as, or more, harmful
and wasteful. Active monitoring for these situations will en-
sure that the vacuum created by removing one procedure is
back-filled by a more effective procedure resulting in better
value for money. This point emphasizes the need for buy-in by
clinicians to mitigate unintended consequences. Monitoring for
these consequences will require a variety of evaluation tech-
niques drawing on both quantitative and qualitative research
methodologies.
CONCLUSION
HTR is not merely an academic exercise. If HTR is to be suc-
cessful it must generate useful knowledge to inform real world
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decisions around the optimal use of technologies. The term “in-
form” is deliberately used here, as it is recognized that research
evidence is only one of many kinds of knowledge that deci-
sion makers use when making these decisions, and that these
decisions are always informed by values. In addition, decision
making is neither rational nor linear, and as Jonathon Lomas
has noted “is not an event; rather it is a generally diffuse, hap-
hazard & somewhat volatile process that is ethereal in nature”
(23).
As one panelist noted, evidence-based guidance can be
viewed as a practical manifestation of social contracts in de-
liberative democracies to ensure the most efficient and ethical
allocation of finite healthcare resources. To achieve this goal, so-
cial values as well as technical issues need to be considered and
guidance developed from HTR should reflect the social/political
milieu.
Healthcare budgets will not continue to increase and we
need to shift our thinking about how we can use these dol-
lars differently with the goal of optimizing “value for money.”
Managing technologies throughout their lifespan is required to
ensure that technologies continue to achieve optimal value for
money. HTR is required to support evidence-informed contin-
ued management. To move this field forward, we must continue
to build on international experiences with a focus on developing
novel methodological approaches to generating, incorporating,
and implementing evidence into policy and practice.
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